Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Change in Cash (2021 - 2025)

Historic Change in Cash for ARS Pharmaceuticals (SPRY) over the last 5 years, with Q3 2025 value amounting to $8.0 million.

  • ARS Pharmaceuticals' Change in Cash rose 16450.02% to $8.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.9 million, marking a year-over-year increase of 19532.93%. This contributed to the annual value of -$20.2 million for FY2024, which is 8555.76% up from last year.
  • According to the latest figures from Q3 2025, ARS Pharmaceuticals' Change in Cash is $8.0 million, which was up 16450.02% from $11.7 million recorded in Q2 2025.
  • ARS Pharmaceuticals' Change in Cash's 5-year high stood at $173.2 million during Q4 2022, with a 5-year trough of -$122.7 million in Q1 2023.
  • For the 5-year period, ARS Pharmaceuticals' Change in Cash averaged around $1.8 million, with its median value being -$7.6 million (2022).
  • Within the past 5 years, the most significant YoY rise in ARS Pharmaceuticals' Change in Cash was 50891.19% (2023), while the steepest drop was 146170.1% (2023).
  • ARS Pharmaceuticals' Change in Cash (Quarter) stood at $121.5 million in 2021, then skyrocketed by 42.61% to $173.2 million in 2022, then plummeted by 93.97% to $10.4 million in 2023, then rose by 6.91% to $11.2 million in 2024, then dropped by 28.16% to $8.0 million in 2025.
  • Its Change in Cash was $8.0 million in Q3 2025, compared to $11.7 million in Q2 2025 and -$11.0 million in Q1 2025.